Grifols S.A Asset Resilience Ratio
Grifols S.A asset resilience ratio. Grifols S.A (G0FB) has an Asset Resilience Ratio of 0.12% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Grifols S.A liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Grifols S.A (2019–2025)
Asset resilience ratio of Grifols S.A from 2019 to 2025. This chart shows how Grifols S.A's Asset Resilience Ratio has changed over time. Read Grifols S.A total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Grifols S.A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see G0FB total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €23.00 Million | 0.12% |
| Total Liquid Assets | €23.00 Million | 0.12% |
Asset Resilience Insights
- Limited Liquidity: Grifols S.A maintains only 0.12% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Grifols S.A Industry Peers by Asset Resilience Ratio
Compare Grifols S.A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
Grifols S.A Asset Resilience Ratio by Year (2019–2025)
Grifols S.A asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Grifols S.A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.12% | €23.00 Million ≈ $26.89 Million |
€19.71 Billion ≈ $23.05 Billion |
+0.02pp |
| 2024-12-31 | 0.10% | €21.18 Million ≈ $24.76 Million |
€21.41 Billion ≈ $25.02 Billion |
+0.03pp |
| 2023-12-31 | 0.07% | €14.93 Million ≈ $17.45 Million |
€20.99 Billion ≈ $24.54 Billion |
-0.13pp |
| 2022-12-31 | 0.20% | €43.26 Million ≈ $50.57 Million |
€21.53 Billion ≈ $25.18 Billion |
-10.35pp |
| 2021-12-31 | 10.55% | €2.03 Billion ≈ $2.37 Billion |
€19.23 Billion ≈ $22.49 Billion |
+10.48pp |
| 2020-12-31 | 0.07% | €10.86 Million ≈ $12.70 Million |
€15.27 Billion ≈ $17.86 Billion |
-11.04pp |
| 2019-12-31 | 11.11% | €1.73 Billion ≈ $2.02 Billion |
€15.54 Billion ≈ $18.17 Billion |
-- |
About Grifols S.A
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, … Read more